We found that OVOL2 (ovo like zinc finger two) was a top candidate; this gene showed a significantly higher expression level in relapsed tumors than in sensitive tumors (Fig. 6C), and a high expression of OVOL2 was associated with cisplatin resistance in cancer cell lines of different lineages (Wilcoxon rank-sum test, p = 4.8 × 10−9, Fig. 6D), and specifically, in ovarian cancer cell lines (Wilcoxon rank-sum test, p = 6.7 × 10−3, Fig. 6E). This evidence concerns the gene OVOL2 and ovarian cancer.